Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
Status:
Completed
Trial end date:
2019-07-16
Target enrollment:
Participant gender:
Summary
This study was designed to test the hypothesis that treatment of HIV infected subjects with
losartan, an agent with specific anti-inflammatory and anti-fibrotic actions, will:
1. reverse existing lymphoid tissue fibrosis,
2. restore lymphoid tissue architecture,
3. increase the number and improve the function of peripheral and lymphatic CD4 T cells,
4. decrease levels of systemic immune activation (IA),
5. decrease size of the HIV reservoir, and
6. be safe and well tolerated.
Phase:
Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute
Collaborators:
Merck Sharp & Dohme Corp. National Institute of Allergy and Infectious Diseases (NIAID)